Quantcast

Industry news that matters to you.  Learn more

Biomarker Predicts Poor Prognosis in African-Americans with Triple-Negative Breast Cancer

Having high levels of a certain biomarker is linked to poor prognosis in African-American patients with triple-negative breast cancer, while the same biomarker doesn’t influence disease outcomes in white patients, according to a new study.

QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced it has acquired an exclusive global license to the biomarker SF3B1 from the University of Tokyo. SF3B1 is believed to play a critical role in the prognosis of patients with myelodysplastic syndromes (MDS), a group of hematological cancers in which bone marrow does not produce enough healthy blood cells. Mutations of this gene, which is an important component of the spliceosome machinery, indicate a more favorable disease progression for patients than the “wild-type” gene, so testing for these gene variants could potentially provide important guidance for treatment based on a personalized healthcare approach to MDS.

PAM50-Based Prosigna Breast Cancer Assay Helps to Identify Patients at Risk of Late Distant Recurrence in a Combined Analysis of 2,137 Patients

NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, recently announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment. Using the Prosigna Assay, the study investigators classified patient tumors by subtype and found that patients with Luminal B subtype have three times higher risk of late distant recurrence than patients with Luminal A subtype tumors. Results were presented at the 2013 San Antonio Breast Cancer Symposium.

Definiens and Metamark Enter Multi-Year Deal for Prostate Cancer Prognostic Test

Definiens, the global leader in image analysis for digital pathology and diagnostics, and Metamark Genetics, a privately-held biotechnology company developing novel tests aimed at improving cancer care, recently announced a multi-year agreement covering use of the Definiens image analysis solution for the ProMark™ prostate cancer prognostic test.

Personalized Medicine Roadmap: Definiens Releases Five Steps to Utilize Data Mining with Image Analysis

Definiens, a healthcare company that advances personalized medicine through image analysis and digital pathology solutions, recently released tips for integrating data mining with image analysis. As pathologists, researchers and clinicians seek to advance personalized medicine through the development and prescription of targeted therapies, data generated through image analysis of digitized tissue sections is becoming essential to stratifying patients and providing personalized care.